Read on Twitter
A thread about $LGVW + @ButterflyNetInc
- Disruptive medical device company focused on imaging that is affordable, easy-to-use, & globally accessible.
- Merger expected to close Q1 2021
- $589M total proceeds: $414M cash in trust + $175M PIPE
- Pro-forma equity value of $2B
- Disruptive medical device company focused on imaging that is affordable, easy-to-use, & globally accessible.
- Merger expected to close Q1 2021
- $589M total proceeds: $414M cash in trust + $175M PIPE
- Pro-forma equity value of $2B
Butterfly iQ+ Handheld Ultrasound-on-Chip™
- Plugs directly into iPhone & works on intuitive app
- Full cardiac, lung, & bladder imaging
- Easy, at-home use with seamless digital transfer to doctor
- Costs under $2K
- Legacy ultrasound tech is 60+ yrs old & 10x as expensive
- Plugs directly into iPhone & works on intuitive app
- Full cardiac, lung, & bladder imaging
- Easy, at-home use with seamless digital transfer to doctor
- Costs under $2K
- Legacy ultrasound tech is 60+ yrs old & 10x as expensive
COVID-19 has put historic stress on our medical infrastructure.
Simplifying & reducing costs on medical imaging is monumental. It will reduce preventable afflictions & expand global use.
@Inc said "This Device Will Change Healthcare Forever".
Video: https://www.youtube.com/watch?v=x9MU7Qy15ZA">https://www.youtube.com/watch...
Simplifying & reducing costs on medical imaging is monumental. It will reduce preventable afflictions & expand global use.
@Inc said "This Device Will Change Healthcare Forever".
Video: https://www.youtube.com/watch?v=x9MU7Qy15ZA">https://www.youtube.com/watch...
Ultrasound market: $8B / Medical imaging market: $21B+
Butterfly can expand this market from only hospitals/med centers to households, ambulances, dialysis, & vet care.
Simple imaging can ID 2/3 of diagnostic conditions, but 2/3 of the world has no access to medical imaging.
Butterfly can expand this market from only hospitals/med centers to households, ambulances, dialysis, & vet care.
Simple imaging can ID 2/3 of diagnostic conditions, but 2/3 of the world has no access to medical imaging.
Butterfly has purchases & agreements with most of the largest 100 hospitals in the US
- 30K+ devices shipped globally
- Healthcare professionals give it an industry-leading net Net Promoter Score of 71
- Available in 20+ countries including US, Canada, most of Europe & Australia
- 30K+ devices shipped globally
- Healthcare professionals give it an industry-leading net Net Promoter Score of 71
- Available in 20+ countries including US, Canada, most of Europe & Australia
Pre-SPAC, backers included @gatesfoundation @BaillieGifford @Fidelity, which grants strategic legitimacy to the growth outlook for Butterly Network.
Investments from healthcare giants like Cigna $CI, Tenet $THC, & $HCA led by Glenview Capital speak to streamlined market access.
Investments from healthcare giants like Cigna $CI, Tenet $THC, & $HCA led by Glenview Capital speak to streamlined market access.
Butterfly Network has transformed the handheld ultrasound space by replacing the piezoelectric crystals (used by competitors like $PHG & $GE) with semiconductor chips (made by $TSM) which allows for broader bandwidth & faster processing to be done inside the probe itself.
CEO @ButterflyNetInc Dr. Jonathan Rothberg is a visionary
- 2013 Recipient of the Presidential Medal of Technology & Innovation for inventing a novel next-gen DNA sequencing method
- Founded 454 Life Science to bring his method to market
- Intimately involved in Butterfly R&D
- 2013 Recipient of the Presidential Medal of Technology & Innovation for inventing a novel next-gen DNA sequencing method
- Founded 454 Life Science to bring his method to market
- Intimately involved in Butterfly R&D
For price action comparison we can look to $NNOX, an ultrasound company also aimed at reducing costs & unit size.
Nano-X IPO& #39;d at $18 and was pushed to a high of $66.67, before selling off in response to @CitronResearch & @muddywatersre short reports.
Market appetite is clear.
Nano-X IPO& #39;d at $18 and was pushed to a high of $66.67, before selling off in response to @CitronResearch & @muddywatersre short reports.
Market appetite is clear.
In summary, $LGVW is an excellent pick for investors looking to gain exposure to healthcare disruption.
2022-2024 roadmap will feature the new Gen3 probe, at-home wearables, & Butterfly Labs is expected to continue to innovate in the space led by visionary CEO Dr. Rothberg.
2022-2024 roadmap will feature the new Gen3 probe, at-home wearables, & Butterfly Labs is expected to continue to innovate in the space led by visionary CEO Dr. Rothberg.
If you enjoyed this thread on $LGVW + @ButterflyNetInc, consider a share & follow for more content like this.
Our other SPAC threads:
$PIC
https://twitter.com/stocktalkweekly/status/1316405256784355330?s=20
https://twitter.com/stocktalk... href="https://twitter.com/search?q=%24RIDE&src=ctag">$RIDE
https://twitter.com/stocktalkweekly/status/1305292561616003072?s=20
https://twitter.com/stocktalk... href="https://twitter.com/search?q=%24TRNE&src=ctag">$TRNE
https://twitter.com/stocktalkweekly/status/1315418176088408065?s=20
https://twitter.com/stocktalk... href="https://twitter.com/search?q=%24SBE&src=ctag">$SBE https://twitter.com/stocktalkweekly/status/1317906852009578497?s=20">https://twitter.com/stocktalk...
Our other SPAC threads:
$PIC
https://twitter.com/stocktalkweekly/status/1316405256784355330?s=20
https://twitter.com/stocktalkweekly/status/1305292561616003072?s=20
https://twitter.com/stocktalkweekly/status/1315418176088408065?s=20
